D
Daniel L. Clarke-Pearson
Researcher at University of North Carolina at Chapel Hill
Publications - 208
Citations - 34363
Daniel L. Clarke-Pearson is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Gynecologic oncology & Ovarian cancer. The author has an hindex of 58, co-authored 207 publications receiving 30602 citations. Previous affiliations of Daniel L. Clarke-Pearson include Durham University & University of Illinois at Chicago.
Papers
More filters
Journal ArticleDOI
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.
TL;DR: A nonparametric approach to the analysis of areas under correlated ROC curves is presented, by using the theory on generalized U-statistics to generate an estimated covariance matrix.
Journal ArticleDOI
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
Peter G. Rose,Brian N. Bundy,E B Watkins,J T Thigpen,G Deppe,M A Maiman,Daniel L. Clarke-Pearson,S Insalaco +7 more
TL;DR: Regimens of radiotherapy and chemotherapy that contain cisplatin improve the rates of survival and progression-free survival among women with locally advanced cervical cancer.
Journal ArticleDOI
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Robert F. Ozols,Brian N. Bundy,Benjamin E. Greer,Jeffrey M. Fowler,Daniel L. Clarke-Pearson,Robert A. Burger,Robert S. Mannel,Koen DeGeest,Ellen M. Hartenbach,Rebecca N. Baergen +9 more
TL;DR: In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin pluspaclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus pac Litaxel.
Journal ArticleDOI
Randomized Comparison of Fluorouracil Plus Cisplatin Versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix With Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study
Charles W. Whitney,William T. Sause,Brian N. Bundy,John H. Malfetano,Edward V. Hannigan,Wesley C. Fowler,Daniel L. Clarke-Pearson,Shu Yuan Liao +7 more
TL;DR: This study demonstrates that for patients with locally advanced carcinoma of the cervix, the combination of 5-FU and CF with RT offers patients better PFS and overall survival than HU, and with manageable toxicity.
Journal ArticleDOI
American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Gary H. Lyman,Alok A. Khorana,Anna Falanga,Daniel L. Clarke-Pearson,Christopher R. Flowers,Mohammad Jahanzeb,Ajay K. Kakkar,Nicole M. Kuderer,Mark Levine,Howard A. Liebman,David S. Mendelson,Gary E. Raskob,Mark R. Somerfield,Paul Thodiyil,David Trent,Charles W. Francis +15 more
TL;DR: Recommendations were developed on the prevention of VTE in hospitalized, ambulatory, and surgical cancer patients as well as patients with established VTE, and for use of anticoagulants in cancer patients without VTE to improve survival.